Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares

Summary

This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will complete device measurements, electronic diary entries, and up to five in-person study visits. The study is based on the idea that changes in skin barrier function may occur before an AD flare becomes visible or symptoms begin.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Atopic Dermatitis

Eligibility basics and study details

Study type

Observational

Phase

Not applicable

Ages

12 to 89 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Castle Biosciences Incorporated

Last updated on ClinicalTrials.gov

October 20, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites